Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Search

We found 2,772 results for "Product Liability Law & Strategy"...

Uncovering the Facts in Litigation And Investigations
February 28, 2014
Over the past decade, the volume of data in litigation and investigations has exponentially increased. As data has become more and more vulnerable to subpoenas and regulators, people have become singularly concerned with making relevance decisions for production. In the process, we have forgotten about focusing on the facts themselves and uncovering the stories within data.
White House Uploads U.S. Cybersecurity Framework
February 28, 2014
President Barack Obama's administration on Feb. 12 released its much-anticipated voluntary cybersecurity framework, giving U.S. companies a common handbook on how they can try to fend off hackers.
Case Notes
February 27, 2014
Recent significant rulings are discussed.
Practice Tip: Personal Jurisdiction from Abroad
February 27, 2014
When a consumer is injured and seeks to recover damages from the manufacturer, can the consumer's home state exercise jurisdiction over the manufacturer? A look at recent cases.
CPSC Poised to Change Voluntary Recall Process
February 27, 2014
The CPSC has proposed an "interpretive rule" that would standardize voluntary recall notices. This article explores the most significant proposed changes and the implications for regulated firms if the CPSC adopts the rule.
Drug & Device News
February 27, 2014
Discussion of news and litigation.
New Jersey Manufacturers and Punitive Damages
February 27, 2014
The state of New Jersey is home to the headquarters of 17 of the top 20 drug-producing companies in the world. These include pharmaceuticals producers Wyeth, Merck and Co. and Johnson & Johnson.
PA Superior Court Confirms CGL Coverage
February 26, 2014
Pennsylvania's intermediate appellate court recently confirmed the availability of CGL coverage for manufacturers facing product liability claims that allege damages to persons and property other than the manufacturers' products.
Blurred Lines
February 26, 2014
Last year brought a number of decisions from various jurisdictions concerning the applicability of the attorney-client privilege and work-product doctrine in the context of an insurer's claims investigation.
The Death Benefit Only Program
February 26, 2014
The DBO program' can be used by employers without regard to corporate and qualified plan limitations and may be provided by employers on a permissibly discriminatory basis.

MOST POPULAR STORIES

  • Surveys in Patent Infringement Litigation: The Next Frontier
    Most experienced intellectual property attorneys understand the significant role surveys play in trademark infringement and other Lanham Act cases, but relatively few are likely to have considered the use of such research in patent infringement matters. That could soon change in light of the recent admission of a survey into evidence in <i>Applera Corporation, et al. v. MJ Research, Inc., et al.</i>, No. 3:98cv1201 (D. Conn. Aug. 26, 2005). The survey evidence, which showed that 96% of the defendant's customers used its products to perform a patented process, was admitted as evidence in support of a claim of inducement to infringe. The court admitted the survey into evidence over various objections by the defendant, who had argued that the inducement claim could not be proven without the survey.
    Read More ›
  • In the Spotlight
    On May 9, 2003, the U.S. Attorney's Office for the District of Massachusetts announced that Bayer Corporation, the pharmaceutical manufacturer, had been sentenced and ordered to pay a criminal fine of $5,590,800 stemming from its earlier plea of guilty to violating the Federal Prescription Drug Marketing Act by failing to list with the FDA its drug product, Cipro, that was privately labeled for an HMO. Such listing is required under the federal Food, Drug &amp; Cosmetic Act. The Federal Prescription Drug Marketing Act, Pub. L. 100-293, enacted on April 22, 1988, as modified on August 26, 1992 by the Prescription Drug Amendments (PDA) Pub. L. 102-353, 106 Stat. 941, amended sections 301, 303, 503, and 801 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. '' 331, 333, 353, 381, to establish requirements for distributing prescription drug samples.
    Read More ›